Immunicon Corporation

The firm represented the creditors' committee in this chapter 11 case in Wilmington, Delaware. The debtors were in the business of developing and commercializing diagnostic and research products for cell analysis and molecular research. The firm’s representation led to the sale of substantially all of the debtors’ assets and a plan a liquidation that paid 100% to unsecured creditors and a dividend to equity holders. Following confirmation of the plan, the firm represented the liquidating trustee administering the debtors’ estate.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.